Jeffrey Gershenwald

17PUBLICATIONS
190CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Law, science and technologyMolecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.

Elizabeth M Burton, Denái R Milton, Michael T Tetzlaff

|Nov 21, 2024
Bills to Restrict Access to and Harm From Indoor Tanning Facilities in US State Legislatures, 1992‒2023.

David B Buller, Julia Berteletti, Carolyn Heckman

|Feb 05, 2024
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.

Alexander H R Varey, Isabel Li, Mary-Ann El Sharouni

|Sep 27, 2022
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.

Andrew W Hahn, Ashley V Menk, Dayana B Rivadeneira

|Jul 09, 2022
Multi-modal molecular programs regulate melanoma cell state.

Miles C Andrews, Junna Oba, Chang-Jiun Wu

Pageof 3